Phase 1 dose escalation study of the allosteric AKT inhibitor BAY 1125976 in advanced solid cancer - lack of association between activating AKT mutation and AKT inhibition-derived efficacy
This open-label, phase I first-in-human study (NCT01915576) of BAY 1125976, a highly specific and potent allosteric inhibitor of AKT1/2, aimed to evaluate the safety, pharmacokinetics, and maximum tolerated dose of BAY 1125976 in patients with advanced solid tumors. Oral dose escalation was investig...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
10 December 2019
|
| In: |
Cancers
Year: 2019, Jahrgang: 11, Heft: 12 |
| ISSN: | 2072-6694 |
| DOI: | 10.3390/cancers11121987 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.3390/cancers11121987 Verlag: https://www.mdpi.com/2072-6694/11/12/1987 
|
| Verfasserangaben: | Andreas Schneeweiss, Dagmar Hess, Markus Joerger, Andrea Varga, Stacy Moulder, Apostolia M. Tsimberidou, Cynthia Ma, Sara A. Hurvitz, Christine Rentzsch, Marion Rudolph, Silke Thiele, Oliver Boix, Gary Wilkinson, Eleni Lagkadinou and Matthias Ocker |
Search Result 1